Peptinovo Biopharma: A Breakthrough In Cancer Treatment
A Portfolio Company update: Peptinovo Biopharma
Peptinovo Biopharma is a private biotechnology company that develops targeted cancer nanomedicines. It focuses on improving chemotherapy effectiveness while reducing side effects.
Based in Ann Arbor, Michigan, Peptinovo Biopharma is developing a new approach to a medical paradoxical challenge. Their researchers are seeking to solve the problem of how to deliver chemotherapy, intended to heal, directly to cancer cells while sparing healthy tissue and quality of life. Chemotherapy forces patients into an impossible tradeoff. The treatment designed to save their lives often comes with devastating physical costs and months spent simply trying to recover from the side effects. While these side effects have become an accepted part of cancer care, the researchers and team at Peptinovo Biopharma believe they don't have to be.
Utilizing Our Body’s Natural Processes
Rather than inventing an entirely new cancer drug, the company's patented PALM™ (Peptide-Amphiphile Lipid Micelle) platform transforms the delivery of existing chemotherapy. Inspired by the body's own "good cholesterol" (HDL), PALM™ acts like a biological Trojan horse, allowing chemotherapy to travel naturally to cancer cells before releasing its therapeutic payload where it is needed most.
In preclinical studies, the technology demonstrated tumor suppression equal to or greater than the current standard of care while showing no evidence of chemotherapy-induced peripheral neuropathy or many of chemotherapy's most debilitating side effects. The idea traces back to Dr. Ren Homan, whose career had already produced breakthrough HDL technologies that ultimately led to the acquisition of his previous company by AstraZeneca. After more than three decades focused on cardiovascular medicine, he began asking a different question: What if the same biology that transports "good cholesterol" throughout the body could also deliver chemotherapy directly to cancer? Together with oncology drug development expert Dr. Bill Elliott, the search for answers became Peptinovo Biopharma.
"Our goal is to preserve everything that makes chemotherapy effective while eliminating as many of the immediate and long-term harmful side effects as possible." - Dr. Ren Homan, Founder & CSO, Peptinovo Biopharma
Approaching a Defining Milestone
The company has received regulatory approval in Australia and is completing its final efficacy study before enrolling the first patients in a Phase 1 clinical trial later in 2026. The dose-escalation study will enroll approximately 18–25 patients with solid tumors, designed to evaluate the therapy's safety profile and determine the maximum tolerated dose before advancing to larger efficacy trials. While this first study will utilize Paclitaxel delivered through the PALM™ platform, the technology is compatible with at least 60% of existing chemotherapy agents, creating the potential to expand its impact across numerous cancer types as future clinical trials progress. With both Australian regulators and the FDA having accepted the safety data supporting human trials, the company anticipates launching U.S. clinical studies in late 2026 or early 2027.
Accelerating Innovation through Philanthropy
For Impact Foundation, relationships like that with Peptinovo Biopharma represent an opportunity to connect mission-minded Donor/Investors with medical innovations that serve people at their most vulnerable. As Peptinovo Biopharma advances toward clinical trials, Donor/Investors are supporting technology designed not only to fight cancer more effectively, but to help patients preserve more of their everyday lives throughout treatment.
I was impressed by what Impact Foundation has created—a way for people to direct their charitable giving toward private companies pursuing missions that otherwise might not be possible. Through this innovative model, groundbreaking technologies like Peptinovo Biopharma's PALM™ platform, whose mission is to help patients beat cancer while living a normal life, can benefit from philanthropic support that accelerates innovation and brings new hope to patients. - Steve Tokarz, CEO, Peptinovo Biopharma
More on the Mission
Innovation begins with bold ideas, but it reaches patients through years of dedicated research, testing, and collaboration. As Peptinovo Biopharma advances toward its first human clinical trials, you can learn more about the company, its mission, and its technology at peptinovo.com.